G35
Conditions
Interventions
Group 1: Adult women of childbearing age undergoing MS relapse therapy
Sponsors
Universitätsklinikum Jena, Klinik für Neurologie
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: - women of full reproductive age (premenopausal) - methylprednisolone (MP) therapy at a dosage of 500–1000 mg for 3–5 days
Exclusion criteria
Exclusion criteria: - antibiotic therapy within three months prior to sample collection - menstruation during sample collection - postmenopausal age
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nugent score after one completed cycle length (qualitative and semi-quantitative composition of the vaginal microecology) Time points of measurement: T0: Immediately before Methylprednisolone therapy; T1: Immediately after the end of Methylprednisolone therapy (after 3–5 days); T2: One cycle length after T0) | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of Hay/Ison criteria, pH analysis, microscopy of native preparations, bacterial culture analysis, Endoplex PCR, 16s-rRNA-sequencing before and after Methylprednisolone Therapy Time points of measurement: T0: Immediately before Methylprednisolone therapy; T1: Immediately after the end of Methylprednisolone therapy (after 3–5 days); T2: One cycle length after T0) | — |
Countries
Germany
Contacts
Public ContactMichelle Dreiling
Universitätsklinikum Jena, Klinik für Neurologie
Outcome results
None listed